TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

This study looks at whether adding a procedure called TIPS (transjugular intrahepatic portosystemic shunt — a connection between blood vessels in the liver to relieve pressure) to standard drug therapy can help patients with advanced liver cancer (hepatocellular carcinoma) that has spread into the main blood vessels of the liver. The drug therapy includes lenvatinib and a PD-1 inhibitor (immunotherapy). **You may be eligible if...** - You have been diagnosed with primary liver cancer (hepatocellular carcinoma) - Your cancer has spread into the main portal blood vessels of the liver (PVTT grade III–IV) - You have high blood pressure in the liver (portal hypertension) caused by the tumor - You have limited spread to other areas (5 or fewer spots across no more than 2 organs) - You are on lenvatinib and PD-1 inhibitor as your first cancer treatment - Your liver function is Child-Pugh class A or B **You may NOT be eligible if...** - You have a history of other cancers - Your liver or blood function is severely impaired - You have severe heart or kidney conditions Talk to your doctor to see if this trial is right for you.